Available Until 11/15/2024

Cardiology Self-Assessment Program (CardSAP) Book 1: Atherosclerotic Cardiovascular Disease (Cert # L249151)

ACPE Numbers: Various – see listing below
Release Date: May 15, 2024
Expiration Dates: November 15, 2024
Activity Type: Application-based
CE Credits: 19 contact hours (BPS and ACPE)
Activity Fee: $80 (ASHP member); $120 (non-member) 

Activity Overview

This course is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by Board of Pharmacy Specialties (BPS). The course consists of 5 learning modules (see table below) and provides up to 19 contact hours of continuing pharmacy education and/or recertification credit. 

Learners will be required to review the content and complete the associated online assessments. The learner must be able to correctly answer the questions based upon their interpretation of the content, as well as “baseline specialty specific knowledge and/or easily retrievable information.” For purposes of this course, “baseline specialty specific knowledge and/or easily retrievable information” is defined as product labeling and well-established standards of practice in the specialty practice. 

These activities are part of the ACCP and ASHP professional development program for BCCP recertification approved by the BPS. 

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.
The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as providers of continuing pharmacy education.

The target audience for Cardiology Self-Assessment Program (CardSAP) Book 1: Atherosclerotic Cardiovascular Disease is board-certified and advanced level cardiology pharmacists.

Board certified pharmacists are eligible to receive up to 19 contact hours of recertification credit for completing this course. To earn recertification credit, learners must review the course content and successfully complete the online assessments by the deadline.   

ASHP provides an opportunity for remediation. Participants who are unsuccessful with the first assessment attempt may take a second assessment. The second assessment is included at no additional cost.

ACCP and ASHP are approved by BPS as a provider for the recertification of BCCP.

Learning Activity

Passing Score

Credit Information

Atherosclerotic Cardiovascular Disease I


4.0 Contact Hours

ACPE: 0217-9999-24-045-H01-P

Atherosclerotic Cardiovascular Disease II


4.0 Contact Hours

ACPE: 0217-9999-24-048-H01-P

Atherosclerotic Cardiovascular Disease III


4.5 Contact Hours


ACPE: 0217-9999-24-047-H01-P

Atherosclerotic Cardiovascular Disease IV


4.0 Contact Hours

ACPE: 0217-9999-24-048-H01-P

Atherosclerotic Cardiovascular Disease V


2.5 Contact Hours

ACPE: 0217-9999-24-049-H01-P

Atherosclerotic Cardiovascular Disease I
ACPE #: 0217-9999-24-045-H01-P
Chapter: Risk Assessment in ASCVD

  • Evaluate individuals for an atherosclerotic cardiovascular disease (ASCVD) risk assessment using a validated risk prediction tool.
  • Distinguish risk factors for ASCVD used in validated risk prediction tools.
  • Evaluate the advantages and disadvantages of the Framingham Risk Score.
  • Evaluate the advantages and disadvantages of the pooled cohort equations risk score.
  • Assess the clinical utility of other validated risk prediction tools.
  • Identify those individuals who should undergo an assessment for ASCVD using additional testing. 

Chapter: New Therapies to Treat Dyslipidemia

  • Assess cardiovascular risk conferred by lipids and lipoproteins.
  • Justify the use of individualized lipid targets based on current evidence and guidelines.
  • Develop a comprehensive plan to optimize lipid-lowering therapy.
  • Evaluate the appropriate use of emerging lipid-lowering therapies. 

Atherosclerotic Cardiovascular Disease II
ACPE #: 0217-9999-24-048-H01-P
Chapter: Nocebo Effects of Statins and Other ASCVD Risk Reduction Therapies

  • Distinguish between placebo, nocebo, and drucebo effects and identify which medications have drucebo effects.
  • Evaluate patients for drucebo effects related to cardiovascular therapies.
  • Demonstrate how statin-associated muscle symptoms impact patient care.
  • Devise a strategy to overcome non-evidence-based advice related to drucebo effects. 

Case Series: Fish Oil Controversies

  • Evaluate the historical data on which consensus recommendations for the use of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are based.
  • Analyze the clinical controversies surrounding the use of omega-3 fatty acids (O3FAs) to reduce cardiovascular (CV) risk.
  • Assess the clinical usefulness of icosapent ethyl in the contemporary management of atherosclerotic CV disease (ASCVD) risk reduction.
  • Evaluate the influence O3FA/EPA/DHA and placebo formulations may have had on outcomes observed in randomized clinical trials.
  • Distinguish patient-specific data and identify risk factors and/or comorbidities that may place the patient at higher risk of adverse effects related to the use of fish oil and its derivatives.
  • Develop a comprehensive plan for managing ASCVD risk with O3FAs in appropriate individuals. 

Atherosclerotic Cardiovascular Disease III
ACPE #: 0217-9999-24-047-H01-P
Chapter: Evolving Antiplatelet Regimens in ASCVD

  • Distinguish patient and procedural characteristics that influence thrombosis and bleeding risk in patients with atherosclerotic cardiovascular disease (ASCVD) requiring antiplatelet therapy.
  • Assess drug-eluting stent characteristics that affect thrombosis risk in patients with ASCVD.
  • Evaluate the strengths and weaknesses of pharmacogenomic-guided strategies in determining antiplatelet therapy.
  • Design an antiplatelet therapy plan that balances thrombosis and bleeding risk in patients with ASCVD 

Chapter: Evolution of β-blockers in ASCVD

  • Distinguish between β-blockers on the basis of receptor specificity.
  • Evaluate the risks and benefits of β-blocker use in patients at risk of atherosclerotic cardiovascular disease (ASCVD).
  • Justify the role for β-blockers in patients with chronic coronary disease and acute coronary syndrome.
  • Design an appropriate antihypertensive regimen in patients with peripheral artery disease and stroke.
  • Justify deprescribing β-blockers in patients at risk of or with ASCVD. 

Atherosclerotic Cardiovascular Disease IV
ACPE #: 0217-9999-24-048-H01-P
Case Series: Lower Extremity Peripheral Arterial Disease

  • Assess at-risk patients for signs or symptoms of lower extremity peripheral artery disease (PAD)
  • Justify the need for atherosclerotic risk-reduction strategies in a person with PAD
  • Evaluate the risk versus benefit of antithrombotic therapy for a patient with asymptomatic PAD
  • Design an antithrombotic treatment regimen for a patient with symptomatic PAD
  • Develop an antithrombotic treatment regimen for a patient who underwent revascularization for PAD 

Case Series: Refractory Angina

  • Based on epidemiologic data, evaluate the prognosis of patients with refractory angina (RA).
  • Use patient-specific data to distinguish among the pathophysiology and the various phenotypes of RA.
  • Develop a patient-specific treatment plan that incorporates a patient's pathophysiology and co-morbidities.
  • Evaluate patients for risk factor modifications and nonpharmacologic treatments for RA.
  • Justify the role of the pharmacist on a specialized team or clinic for the management of RA. 

Atherosclerotic Cardiovascular Disease V
ACPE #: 0217-9999-24-049-H01-P
Case Series: Biostatistical Application in ASCVD

  • Assess the strength of evidence for a study according to its design.
  • Assess data and variable types, including how they are summarized in studies.
  • Evaluate the efficacy or safety of an intervention by interpreting the statistical comparison of summarized data points between treatment arms.
  •  Apply study results to clinical decisions in practice using biostatistics and study design principles.

In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company. 

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience. 

The following persons in control of this activity’s content have relevant financial relationships:

Consultancies: Adam Bress (Dose Spot); Mary Katherine Cheeley (Novartis Corporation); James C. Coons (Merck, Pfizer-Bristol Myers Squibb Alliance); Robert J. DiDomenico (Abiomed, PhaseBio Pharmaceuticals); Paul P. Dobesh (Pfizer/BMS Alliance, Janssen); Steven P. Dunn (Abiomed); Laney K. Jones (Novartis); Kristin Watson (Wolters-Kluwer)

Honoraria: Snehal Bhatt (Janssen Pharmaceuticals, Inc.)

Grants: Arden R. Barry (University of British Columbia, Shoppers Drug Mart Professorship in Clinical pharmacy); Adam Bress (NIH, NIH-NIA [two grants]); Mary Katherine Cheeley (Novartis); James C. Coons (Heart Rhythm Society); Robert J. DiDomenico (CSL Behring); Dave L. Dixon (Boehringer Ingelheim); Kristin Watson (University of Maryland Baltimore)

All other persons in control of content do not have any relevant financial relationships with an ineligible company. 

As required by the Standards of Integrity and Independence in Accredited Continuing Education, all relevant financial relationships have been mitigated prior to the CPE activity.

Activities consist of educational materials, assessments, and activity evaluations. In order to receive continuing pharmacy education credit, learners must:

  • Complete the attestation statement
  • Review all content
  • Complete and pass the assessments
  • Complete the evaluations 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 

ACCP and ASHP collaborate on cardiology pharmacy activities.